Structure Therapeutics Reports Breakthrough in Obesity Study

Structure Therapeutics, Inc. Sponsored ADR (GPCR) just unveiled an announcement.

Structure Therapeutics Inc. has announced promising results from its Phase 2a obesity study, revealing a significant weight loss in participants using their novel oral GLP-1 receptor agonist, GSBR-1290. The study showed a mean weight reduction of 6.2%, with a third of participants losing 10% of their body weight. Additionally, the new tablet formulation of the drug proved effective and well-tolerated, with plans to begin a 36-week Phase 2b obesity study by the end of 2024. This news could signal a breakthrough in non-peptide, small molecule treatments for obesity, positioning Structure Therapeutics as a potential leader in the market.

Learn more about GPCR stock on TipRanks’ Stock Analysis page.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.